title: Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
abstract: The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) is a recently identified fusion-type oncoprotein that exists in approximately 5% of non-small cell lung cancer (NSCLC). It has been demonstrated that NSCLC driven by EML4-ALK is strongly addicted to this fusion-type oncokinase. A clinical trial of crizotinib (PF-02341066) sponsored by Pfizer has proven this oncogene addiction in humans by demonstrating a high response rate to inhibition of ALK kinase activity. In the present study, we report on three cases harboring EML4-ALK rearrangement who were enrolled in the trial (A8081001, NCT00585195). All three patients showed favorable responses to the ALK-specific tyrosine kinase inhibitor.
authors.affiliation: Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan. tkijima@imed3.med.osaka-u.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Kijima
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tetsumoto
authors.forename: Kazuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Ryo
authors.initials: R
authors.lastname: Takahashi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Hirata
authors.forename: Izumi
authors.initials: I
authors.lastname: Nagatomo
authors.forename: Shigenori
authors.initials: S
authors.lastname: Hoshino
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kida
authors.forename: Sho
authors.initials: S
authors.lastname: Goya
authors.forename: Isao
authors.initials: I
authors.lastname: Tachibana
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D000077547:Crizotinib; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib